Patients experience with preoperative use of anti-obesity medications and associations with bariatric surgery expectations.-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Patients experience with preoperative use of anti-obesity medications and associations with bariatric surgery expectations.

Published:2024-09 Issue: Volume: Page:
ISSN:1550-7289
Container-title:Surgery for Obesity and Related Diseases
language:en
Short-container-title:Surgery for Obesity and Related Diseases

Author:

Samuels Jason M.^ORCID,Patel Mayur,Roumie Christianne L.,Self Wesley^ORCID,Funk Luke^ORCID,Spann Matthew^ORCID,Niswender Kevin

Funder

National Center for Advancing Translational Sciences

Publisher

Elsevier BV

Reference24 articles.

1. Tirzepatide Once Weekly for the Treatment of Obesity;Jastreboff;The New England journal of medicine,2022

2. Once-Weekly Semaglutide in Adults with Overweight or Obesity;Wilding;The New England journal of medicine,2021

3. FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems. PR Newswire. 2023.

4. FDA approves Lilly diabetes drug Mounjaro for weight loss;Gilbert;The Washington post,2023

5. Antiobesity Medication Use in 2.2 Million Adults Across Eight Large Health Care Organizations: 2009-2015;Saxon;Obesity (Silver Spring),2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP